Pharmidex partners in European Commission H2020 award
May 21, 2017

Pharmidex joins Horizon 2020 EU project to work on radioactive contamination

Pharmidex partners in European Commission H2020 award

This project aims to stimulate intersectoral and international collaboration within Europe and with an ICPC country, Kazakhstan, in the area of novel nanoporous and nanostructured adsorbents for the treatment of very serious health conditions associated with acute and chronic exposure to external radiation and uptake of heavy metals and radiation as a consequence of accidental, occupational or deliberate activities and events.


This can dramatically lower the quality of life of the people affected and at present the treatment available is costly and inefficient. Radioactive contamination is a particularly serious problem in two of the countries participating in this project, namely, Ukraine and Kazakhstan, on large territories of the Chernobyl zone and around Semipalatinsk nuclear test site, respectively.


A large number of people are affected by living in the areas with elevated level of radioactivity with uncertain long-term consequences to their health and the health of future generations.


The expected impact of the project results is development of efficient and cost-effective methods of protection of first responders, population and cancer patients treated with radiotherapy from elevated doses of external and incorporated radiation and for occupational health protection of personnel working and the population living in areas contaminated with heavy metals.


Please find more information on the following web page: http://cordis.europa.eu/project/rcn/207057_en.html

April 29, 2026
We’re pleased to introduce the Pharmidex Senior Management Team (SMT), bringing together expertise across drug discovery, bioanalysis, DMPK, and translational science: 🔹 Alix Hampson 🔹 Dr Mansoor Chishty 🔹 Prof Mo Alavijeh (FRSC, FRSM) 🔹 Dr Martin Barrett 🔹 Dr Stephen Mitchell 🔹 Ash Alavijeh Collectively, the team brings 150+ years of combined experience, supporting programmes from discovery through to the clinic and beyond. We’ve also seen firsthand how similar pieces, in the hands of our 400+ innovative clients, can be combined to unlock real impact for patients. To mark the occasion, we’ve reimagined our SMT in LEGO style 🧱 Much like LEGO: • Great things are built step by step • Every piece has a purpose • The best outcomes come from creativity, collaboration, and continuous evolution At Pharmidex, it’s about bringing the right pieces together, to build smarter solutions and better outcomes.
April 27, 2026
The success of your research starts with the right model, at the right time. At Pharmidex, we deliver tailored GA breeding solutions combining expert colony management, flexible study design, and rigorous quality control. Backed by AAALAC-accredited facilities and a strong commitment to the 3Rs, we ensure reliable, study-ready models with full traceability. From breeding strategy and genotyping to scalable capacity and flexible timelines, we act as an extension of your team, helping accelerate your research with confidence. 🔬 The right models. When you need them. 🚀 Flexible. Reliable. Research-focused. Let’s build your next breeding strategy.
April 20, 2026
Pharmidex is pleased to announce that Ian Knowles and Janette Dalay Robertson , will be attending TARGET TO PATIENT 2026 (T2P26) on Monday 20th – Tuesday 21st April 2026 at the Hinxton Hall Conference Centre, Wellcome Genome Campus, Cambridge, UK. They look forward to meeting founders, investors and biotech leaders to discuss drug discovery, translational partnerships and life science investment opportunities. Feel free to catch them for a chat!
More Posts